Bayer ROE 2010-2024 | BAYRY

Current and historical return on equity (ROE) values for Bayer (BAYRY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Bayer ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-12-31 $-2.76B $34.68B -7.57%
2024-09-30 $-2.95B $33.75B -8.03%
2024-06-30 $-3.32B $38.60B -8.88%
2024-03-31 $-3.35B $38.83B -8.84%
2023-12-31 $-3.18B $35.80B -8.12%
2023-09-30 $-4.25B $36.51B -10.48%
2023-06-30 $1.28B $40.48B 3.05%
2023-03-31 $3.02B $44.03B 7.21%
2022-12-31 $4.37B $41.01B 10.56%
2022-09-30 $5.30B $41.77B 12.93%
2022-06-30 $4.85B $40.66B 12.19%
2022-03-31 $2.36B $42.20B 6.08%
2021-12-31 $1.18B $39.24B 3.05%
2021-09-30 $-0.10B $36.88B -0.26%
2021-06-30 $-3.41B $36.84B -9.04%
2021-03-31 $-11.11B $41.92B -29.00%
2020-12-31 $-11.99B $35.07B -29.03%
2020-09-30 $-10.51B $36.80B -22.94%
2020-06-30 $-6.15B $39.49B -12.44%
2020-03-31 $4.82B $53.82B 9.22%
2019-12-31 $4.58B $53.22B 8.74%
2019-09-30 $-1.69B $51.32B -3.21%
2019-06-30 $0.51B $50.52B 0.94%
2019-03-31 $1.01B $54.61B 1.80%
2018-12-31 $2.00B $54.50B 3.70%
2018-09-30 $7.49B $58.62B 14.69%
2018-06-30 $8.69B $56.31B 19.94%
2018-03-31 $9.08B $47.18B 23.14%
2017-12-31 $8.29B $41.66B 24.34%
2017-09-30 $7.98B $29.13B 24.58%
2017-06-30 $4.75B $39.03B 14.78%
2017-03-31 $4.96B $26.40B 17.02%
2016-12-31 $5.02B $35.30B 17.08%
2016-09-30 $5.26B $27.66B 19.05%
2016-06-30 $5.04B $27.15B 18.71%
2016-03-31 $4.76B $27.33B 18.04%
2015-12-31 $4.56B $28.25B 17.74%
2015-09-30 $4.06B $25.12B 15.99%
2015-06-30 $4.04B $24.80B 15.65%
2015-03-31 $4.08B $24.68B 15.48%
2014-12-31 $4.55B $26.88B 16.63%
2014-09-30 $4.99B $26.92B 18.09%
2014-06-30 $4.86B $26.81B 17.67%
2014-03-31 $4.65B $28.91B 17.12%
2013-12-31 $4.24B $27.63B 16.00%
2013-09-30 $4.08B $26.69B 15.96%
2013-06-30 $3.77B $25.46B 15.23%
2013-03-31 $3.30B $26.13B 13.58%
2012-12-31 $3.15B $23.88B 12.92%
2012-09-30 $3.21B $23.41B 12.78%
2012-06-30 $3.46B $23.84B 13.30%
2012-03-31 $3.90B $26.31B 14.52%
2011-12-31 $3.45B $26.84B 12.81%
2011-09-30 $2.72B $26.91B 10.25%
2011-06-30 $2.17B $27.22B 8.44%
2011-03-31 $1.77B $26.87B 7.07%
2010-12-31 $1.75B $25.09B 6.97%
2010-09-30 $2.16B $23.75B 8.52%
2010-06-30 $2.18B $24.25B 8.37%
2010-03-31 $2.23B $27.19B 8.51%
2009-12-31 $1.87B $26.43B 7.49%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $23.657B $50.438B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $796.425B 64.61
Johnson & Johnson (JNJ) United States $379.479B 15.67
AbbVie (ABBV) United States $306.016B 17.09
Novo Nordisk (NVO) Denmark $260.636B 17.65
Roche Holding AG (RHHBY) Switzerland $248.102B 0.00
Novartis AG (NVS) Switzerland $234.183B 14.19
Merck (MRK) United States $196.697B 10.21
Sanofi (SNY) France $128.587B 12.24
Pfizer (PFE) United States $125.566B 7.12
Innoviva (INVA) United States $1.145B 10.56